CMS Open Payments · Program Year 2024
Magenta Medical Inc
Magenta Medical Inc reported $440,433.80 across General Payments, Research, and Ownership to 39 physicians and teaching hospitals across 73 transactions.
- $440.4K Above-median payer
- All-tracks total
- 73 Below-median volume
- Transactions
- 39 Below-median reach
- Recipients
- +$31.6K
- General Payments vs PY2023
Magenta Medical Inc reported $440,433.80 across all CMS Open Payments tracks (General + Research + Ownership) to 39 physicians and teaching hospitals in Program Year 2024 - ranking #794 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $47,854.28, averaging $11.3K per recipient.
How Magenta Medical Inc's $440.4K all-tracks total breaks down
Magenta Medical Inc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
21/100
Total payments
F
14/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer magenta-medical-inc Magenta Medical Inc
$440.4K · #794/1,925 · 0.0% industry · PY2024
- TOT $440.4K
- RANK #794
- SHARE 0.0%
- TXN 73
- RCP 39
- CAT 4
- GEN $47.9K
- ΔGEN +$31.6K
- TOP1 19.1%
- PY 2024
Volume peers
Nearest volume peer: RedDress LTD ($439.2K)
Magenta Medical Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Magenta Medical Inc's CMS-reported General Payments increased by $31.6K (+193.8%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2023: MAGENTA MEDICAL INCPY2024: MAGENTA MEDICAL INC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $16,285.89
- PY2024
- $47,854.28
What the Data Shows for Magenta Medical Inc
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Magenta Medical Inc, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
11 transactions worth $37.4K make "Consulting Fee" the top general-payment category in the 4-category breakdown below, 78.2% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Consulting Fee" leads Magenta Medical Inc's 4-category general-payment breakdown at $37.4K, 78.2% of the reported total.
Magenta Medical Inc reports 4 general-payment categories - the top three are Consulting Fee (78.2%), Compensation for Services Other Than Consulting (11.5%), and Travel and Lodging (9.5%). The remaining 1 category make up 0.8% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Magenta Medical Inc divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $37.4K | 11 | 78.2% |
| Compensation for Services Other Than Consulting | $5.5K | 11 | 11.5% |
| Travel and Lodging | $4.6K | 13 | 9.5% |
| Food and Beverage | $402.32 | 4 | 0.8% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $30,364.41 (63.5%) of $47,854.28 in this company's General Payments records across 14 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Magenta Medical Inc
The five named recipients with the highest reported General Payments from this company
- 1
Duane S Pinto
$9,144.47 across 5 reported transactions
- 2
Robert W Yeh
$6,556.02 across 2 reported transactions
- 3
Mir B Basir
$4,985.74 across 4 reported transactions
- 4
Farouc a Jaffer
$4,955.11 across 4 reported transactions
- 5
Mohanjit S Brar
$4,723.07 across 4 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Magenta Medical Inc's spend rank (#794 of 1,925, top 41% by spend) and concentration rank (#1,003 of 1,838, bottom 45% least concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Ion Beam Applications S.A. : $32.3K total payments, HHI 1083
- Cumberland Pharmaceuticals, Inc. : $341.4K total payments, HHI 1083
- Cook Incorporated : $6.0M total payments, HHI 1081
- Grifols Shared Services North America, Inc. : $105.0K total payments, HHI 1080
- BioCryst Pharmaceuticals, Inc. : $326.1K total payments, HHI 1076
- Vektor Medical Inc. : $86.8K total payments, HHI 1068
- Magenta Medical Inc (this company) : $47.9K total payments, HHI 1068
- Galvanize Therapeutics, Inc : $228.2K total payments, HHI 1067
- Mesh Suture Inc : $11.2K total payments, HHI 1063
- Akebia Therapeutics Inc : $497.0K total payments, HHI 1056
- Omnia Medical, LLC : $2.0M total payments, HHI 1054
- Afaxys, Inc. : $17.3K total payments, HHI 1054
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Magenta Medical Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Magenta Medical Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Magenta Medical Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Emergent BioSolutions Inc.
Caption Health, Inc.
Secura Bio, Inc.
Asahi Intecc USA, Inc.
PhotoniCare Inc
Put this to use
Magenta Medical Inc ranks #794 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Magenta Medical Inc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.